Program
c-Met Inhibitor ANS014004
Also written as “ANS014004” and “ANS014004 + PLB1004”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Avistone Biotechnology | 22 open or running | phase 1since Feb 27, 2024 | Feb 27, 2024 | Apr 2027phase 1 · NCT06307795 |
| Beijing Pearl Biotechnology Limited Liability | 11 open or running | phase 2since Nov 4, 2025 | Nov 4, 2025 | Dec 2029phase 2 · NCT07285148 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 27, 2024First study: phase 1 study in Locally Advanced or Metastatic Solid TumorsNew to Avistone BiotechnologyAvistone Biotechnology · NCT06328439 · 40 enrolled · China
- Mar 5, 2024Phase 1 study in Locally Advanced or Metastatic Solid TumorsAvistone Biotechnology · NCT06307795 · 63 planned · United States, Canada, China
- Nov 4, 2025Beijing Pearl Biotechnology Limited Liability’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Beijing Pearl Biotechnology Limited LiabilityBeijing Pearl Biotechnology Limited Liability · NCT07285148 · 253 planned · United States
Ahead
- Apr 2027Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsAvistone Biotechnology · NCT06307795
- Dec 31, 2027Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsAvistone Biotechnology · NCT06328439
- Dec 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungBeijing Pearl Biotechnology Limited Liability · NCT07285148
TargetBeta
“An orally bioavailable, next-generation, type II inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule
Other programs on MET
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Crizotinibrule | Pfizer | phase 4 | 31 |
| telisotuzumab adizutecan | AbbVie | phase 3 | 18 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| vebreltinibrule | Beijing Pearl Biotechnology Limited Liability | phase 3 | 9 |
| glumetinibrule | Haihe Biopharma | phase 3 | 8 |
| vilzemetkib | Sino Biopharmaceutical | phase 3 | 8 |
| dalmelitinib | Hansoh Pharmaceutical Group | phase 3 | 7 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| SHR-1826 | Jiangsu HengRui Medicine | phase 2 | 7 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07285148Carcinoma, Non-Small-Cell Lung · United States | 2 | Not yet recruiting | Beijing Pearl Biotechnology Limited Liability | Dec 2029 | 253 |
| NCT06307795Locally Advanced or Metastatic Solid Tumors · United States, Canada, China | 1 | Recruiting | Avistone Biotechnology | Apr 2027 | 63 |
| NCT06328439Locally Advanced or Metastatic Solid Tumors · China | 1 | Active, not recruiting | Avistone Biotechnology | Dec 31, 2027 | 40 |
How it is read
Names in the registry
- “ANS014004”, 2 entries
- “ANS014004 + PLB1004”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.